New hope for hodgkin lymphoma relapse: targeted drugs and immunotherapy under trial
NCT ID NCT07572123
First seen May 12, 2026 · Last updated May 15, 2026 · Updated 1 time
Summary
This study looks at two groups of people whose Hodgkin lymphoma has come back or not responded to first treatment. For standard-risk patients, it compares a new approach (targeted drug and immunotherapy after radiation) to the usual high-dose chemo plus stem cell transplant. For high-risk patients, it adds an immunotherapy drug after the usual transplant. The goal is to see if these combinations keep the cancer from returning longer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT CLASSIC HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.